Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 58 clinical trials
Featured trial
A Phase 1b, Dose-escalation Study of Pexa-Vec (Thymidine Kinase-Deactivated Vaccinia Virus Plus GM-CSF) in Combination With REGN2810 (Anti-PD-1) in Patients With Metastatic or Unresectable Renal Cell Carcinoma (RCC)

This is a Phase 1b, open-label, multi-center, dose-escalation trial of Pexa-Vec plus REGN2810 in patients with metastatic or unresectable renal cell carcinoma (RCC). The trial consists of a dose-escalation stage, where the maximum feasible dose of Pexa-Vec in combination with REGN2810 will be determined, followed by an expansion stage. During …

cancer
measurable disease
renal function tests
renal cell cancer
systemic therapy
  • 2 views
  • 23 Nov, 2020
  • 3 locations
A Randomized, Double-blind, Placebo-controlled Clinical Trial of Once-daily Inhaled Molgramostim Nebulizer Solution in Adult Subjects With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (IMPALA-2)

160 subjects with autoimmune pulmonary alveolar proteinosis (aPAP) will be randomized to receive once daily treatment with inhaled molgramostim or placebo for 48 weeks. Subjects completing the 48 week placebo-controlled period will receive open-label treatment with once daily inhaled molgramostim for 48 weeks.

  • 1 views
  • 18 Oct, 2022
  • 49 locations
GM-CSF Fosfomycin and Metronidazole for Pouchitis in Ulcerative Colitis Patients After Restorative IPAA Surgery

This study will examine whether the application of GM-CSF, fosfomycin and metronidazole locally in the pouch is safe and effective in the treatment of pouchitis for patients with ulcerative

  • 0 views
  • 20 Sep, 2021
  • 1 location
Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma

The purpose of this study is to find out what effect an antibody called Humanized 3F8 (Hu3F8) and a drug called GM-CSF have on the patient and whether it can keep the patient in remission longer

neutrophil count
blood transfusion
monoclonal antibodies
hu3f8
platelet count
  • 8 views
  • 04 Oct, 2022
  • 3 locations
Hypofractionated Radiotherapy Combined With PD-1 Inhibitor Sequential GM-CSF and IL-2 for the Treatment of Advanced Refractory Solid Tumors (PRaG2.0)

This is a prospective multicenter clinical study to determine the efficacy and safety of hypofractionated radiotherapy combined with PD-1 inhibitor sequential GM-CSF and IL-2 for advanced

  • 0 views
  • 04 Oct, 2022
  • 5 locations
OH2 Oncolytic Viral Therapy in Advanced Bladder Cancer

factor (GM-CSF) may induce a more potent antitumor immune response.

  • 0 views
  • 04 Oct, 2022
  • 1 location
OH2 Oncolytic Viral Therapy in Non-Muscle-Invasive Bladder Cancer

gene encoding human granulocyte macrophage colony-stimulating factor (GM-CSF) may induce a more potent antitumor immune response.

  • 0 views
  • 04 Oct, 2022
  • 1 location
A Phase II Study of Naxitamab Added to Induction Therapy for Subjects With Newly Diagnosed High-Risk Neuroblastoma

This is a prospective, multicenter clinical trial in subjects with newly diagnosed high-risk neuroblastoma to evaluate the efficacy and safety of administering naxitamab with standard induction therapy. The initial chemotherapy will include 5 cycles of multi-agent chemotherapy. Naxitamab will be added to all 5 Induction cycles. Subjects with an ALK …

  • 0 views
  • 18 Oct, 2022
  • 1 location
Randomized Trial of Curcumin to Reduce Mucositis in Autologous Transplant Setting

Mucositis is a very common complication in bone marrow transplant setting. It is a result of injury to the gut caused by high dose chemotherapy. Currently there are no universal protocols that have been accepted as a standard to prevent and treat mucositis in the transplant setting. Post transplant upto …

  • 0 views
  • 30 May, 2021
  • 1 location
UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma

melanoma. This study will explore the Efficacy and Safety of UV1 administered with GM-CSF in combination with nivolumab and ipilimumab.

cancer
neutrophil count
direct bilirubin
nivolumab
immunologic adjuvant
  • 0 views
  • 04 Oct, 2022
  • 36 locations